EClinCloud Surpasses 1,100 Clinical Trials Across 10+ Countries as Its Unified AI-Driven Platform Expands Worldwide

China-built clinical research platform now serves 300+ pharmaceutical, biotech and CRO organizations and 20,000+ users, uniting EDC, RTSM, eCOA, independent review, CTMS and eTMF with embedded AI agents on a single data model.

NINGBO, China, Sept. 3, 2026 /PRNewswire/ -- EClinCloud (Ningbo) Technology Co., Ltd., developer of a unified, AI-driven clinical research platform, today announced that its technology now supports more than 1,100 clinical trials for 300+ sponsor and research organizations in 10+ countries and regions, including the United States, Canada, the United Kingdom, Spain, Poland, Pakistan, Georgia, Australia, New Zealand and China. The company says the milestones reflect its market position: connected clinical evidence on one platform — built in China, engineered to global standards, and ready for studies worldwide.

EClinCloud replaces the patchwork of point systems that many trials still run on. The platform combines electronic data capture (EDC), randomization and trial supply management (RTSM), electronic clinical outcome assessments (eCOA), independent review committee (IRC) services, clinical trial management (CTMS), electronic trial master file (eTMF), resource management and eLearning on one data model, one audit trail and one workflow engine. Data entered once is visible in real time to every authorized role, and documents file continuously to the eTMF for inspection readiness.

At EClinCloud, artificial intelligence is not an add-on but the company's founding premise. Built as an AI-native clinical trial company, EClinCloud has explored the fusion of AI and clinical research since its inception — pairing deep AI engineering capability with equally deep clinical research expertise, as AI continues to gain momentum across the global clinical research market. Role-based agents parse protocols to auto-configure study builds, which the company reports cuts build effort by roughly 60%; capture source data by medical OCR at 95%+ accuracy across 1,000+ form types; and model trial risk in real time for project managers. In 2026 EClinCloud launched its embedded AI agent and next-generation IRC platform, and its AI management system is certified to ISO/IEC 42001:2023, alongside ISO 27001/27701 security certifications and workflows aligned with 21 CFR Part 11, EU Annex 11, ICH GCP, GDPR and HIPAA.

"Clinical research is evolving rapidly across global markets," said Michael Qin, PhD, Founder and Chief Executive Officer of EClinCloud. "We built this platform inside one of the world's highest-volume trial environments and engineered it to international standards from day one. When data, operations and endpoint assessment share one backbone, teams see issues earlier and decide with confidence — in any market."

The company's customer base — 54% pharmaceutical companies, 23% biotechs and 17% contract research organizations, with device manufacturers and research institutions making up the remainder — positions EClinCloud as an alternative to multi-vendor eClinical stacks for sponsors running multi-regional trials. Headquartered in Ningbo with offices in Beijing, Shanghai, Chengdu, Shenzhen and New York, and teams operating across China, the U.S., Japan and Singapore, EClinCloud pairs local operating knowledge with region-ready workflows and 24/7 multilingual support.

For demonstrations and partnership inquiries, visit https://eclincloud.com/demo.

About EClinCloud
EClinCloud (Ningbo) Technology Co., Ltd. builds a unified, AI-driven clinical cloud platform and endpoint assessment technology for global pharmaceutical and research organizations, with a mission to become a global leader in AI-driven clinical research. Its integrated platform — EDC, RTSM, eCOA, IRC, CTMS, eTMF, resource management and eLearning, with embedded AI agents and BI analytics — supports 1,100+ clinical trials, 300+ organizations and 20,000+ users in 10+ countries and regions. EClinCloud is headquartered in Ningbo, China, with offices in Beijing, Shanghai, Chengdu, Shenzhen and New York. More information is available at https://eclincloud.com.

Company Contact
EClinCloud — Global Inquiries
Phone: +86 186 1698 7169
Email: [email protected]
Web: https://eclincloud.com/demo

Media Relations
EClinCloud — Press Inquiries
Phone: +1 415 689 1868
Email: [email protected]

SOURCE EClinCloud